Cam­bridge's TriNetX rais­es $40M for clin­i­cal an­a­lyt­ics plat­form; Nov­aBay chops its sales force, ap­points new chief

Mer­ck Glob­al Health In­no­va­tion Fund has led a $40 mil­lion Se­ries D to sup­port TriNetX in build­ing out and ex­pand­ing the reach of its clin­i­cal an­a­lyt­ics plat­form based on re­al-world ev­i­dence in­volv­ing 300 mil­lion pa­tients. The Cam­bridge, MA-based com­pa­ny — led by CEO Ga­di Lach­man — said it will use the funds to ac­cel­er­ate on­go­ing com­mer­cial­iza­tion in Eu­rope, Asia and South Amer­i­ca, adding to its bio­phar­ma and CRO cus­tomer base as well as health­care net­work. New in­vestors Mit­sui & Co, ITOCHU Tech­nol­o­gy Ven­tures, ITOCHU Cor­po­ra­tion, and ex­ist­ing in­vestors MPM Cap­i­tal, F2 Ven­tures, and Deer­field Man­age­ment are al­so bet­ting on TriNetX’s po­ten­tial to dri­ve clin­i­cal tri­al de­sign.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.